CDT Equity (CDT) Cash from Investing Activities (2022 - 2025)
CDT Equity's (CDT) quarterly Cash from Investing Activities came in at $595000.0 in Q4 2025, up 600.0% YoY from $85000.0 in Q4 2024, and up 159.62% on a QoQ basis from -$998000.0 in Q3 2025.
CDT Equity (CDT) Cash from Investing Activities (2022 - 2025) Analysis & Trends
CDT Equity (CDT) has 4 years of Cash from Investing Activities data on file, last reported at $595000.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 600.0% year-over-year to $595000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$808000.0 (down 208.46% YoY) and the FY2025 annual result came in at -$808000.0, down 1779.07% from the prior year.
- Cash from Investing Activities rose to $595000.0 in Q4 2025, from -$998000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $134.8 million in Q3 2022 to a low of -$134.9 million in Q1 2022.
- A 4-year average of -$6538.5 and a median of $67000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 1020.37% — and 2025, when it plunged 1139.58%.
- Tracing CDT's Cash from Investing Activities over 4 years: stood at -$54000.0 in 2022, then soared by 1020.37% to $497000.0 in 2023, then slumped by 82.9% to $85000.0 in 2024, then surged by 600.0% to $595000.0 in 2025.
- The last three Cash from Investing Activities figures came in at $595000.0 (Q4 2025), -$998000.0 (Q3 2025), and -$1000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 595,000.00 |
| Dec 31, 2025 | 595,000.00 |
| Sep 30, 2025 | -998,000.00 |
| Sep 30, 2025 | -998,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -404,000.00 |
| Mar 31, 2025 | -404,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Sep 30, 2024 | 96,000.00 |
| Sep 30, 2024 | 96,000.00 |
| Dec 31, 2023 | 497,000.00 |
| Dec 31, 2023 | 497,000.00 |
| Sep 30, 2023 | 67,000.00 |
| Sep 30, 2023 | 67,000.00 |
| Jun 30, 2023 | 404,000.00 |
| Jun 30, 2023 | 404,000.00 |
| Mar 31, 2023 | -243,000.00 |
| Mar 31, 2023 | -243,000.00 |